All-trans Retinoic Acid,Arsenic Trioxide,and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status

• 作者: Lin-wei XU Yong-zhong SU Hong-fang TAO
• 来源期刊: 当代医学科学（英文）
• 年，卷（期）: 2021,（3）
• 所属期刊栏目: HEMATOLOGY COLUMN
• 页码范围: 491-497
• 页数: 7页
• 语种: 英文
• DOI: 10.1007/s11596-021-2377-3

摘要

All-trans retinoic acid(ATRA)and pre-upfront arsenic trioxide(ATO)have revolutionized the therapy of acute promyelocytic leukemia(APL).However,internal tandem duplication of FMS-like tyrosine kinase 3(FLT3-ITD)mutations is associated with increased risk of relapse.The aim of this study was to analyze the prognostic impact of FLT3-ITD on APL patients who received remission induction with ATRA,idarubicin(IDA)and/or ATO,followed by ATRA plus ATO along with anthracycline,as consolidation therapy.A total of 72 patients newly diagnosed with APL were included in this study.83.3％of the patients achieved complete remission(CR)after induction therapy.FLT3-ITD mutations were detected in 16(22.2％)patients and closely related to bcr-3 PML-RARa transcript(P＜0.00l).The 5-year overall survival(OS)rate was 100％in both FLT3-ITDpositive and FLT3-ITDnegatve groups,and there was no significant difference in 5-year event-free survival(EFS)between the two groups(78.3％vs.83.3％,P=0.85).ATRA plus ATO and anthracycline-based chemotherapy achieved great outcome in newly diagnosed APL regardless of the FLT3-ITD mutation status.